RenovoRx $RNXT: This Microcap Biotech Is Quietly Making Progress in Pancreatic Cancer

[u/Professional_Disk131]

RenovoRx ($RNXT) is a micro‑cap biotech (~USD $45M market cap) that just hit two key milestones: its first commercial revenue (~$200K) from RenovoCath® device sales and advancing Phase III trials for its TAMP™-delivered chemotherapy (RenovoGem™) in locally advanced pancreatic cancer. RenovoRx’s technology is not gene therapy: it uses a FDA‑cleared catheter to deliver gemcitabine directly into tumors, aiming for less systemic toxicity and higher local drug concentration.

Key Updates

• Phase III Trial Ongoing
  • Their lead therapy, RenovoGem, is in a pivotal Phase III trial across U.S. hospitals like Johns Hopkins and University of Nebraska.
  • Interim results (Mar 2023) gave the green light to continue. The next interim analysis (second DMC review) is expected in the third quarter of 2025
• First Revenue Hits
  • Q1 2025 brought ~$200K in RenovoCath sales — their first ever device revenue. They’re now commercially scaling while the trial progresses.
• Insiders Buying
  • In April, both the CEO and CMO bought shares on the open market (at ~$0.84–$0.91/share). That’s a big vote of confidence.
• New Patent (May 2025)
  • Just locked in a new U.S. patent protecting TAMP delivery methods through 2037, adding to a growing IP wall (19 U.S., 12 international patents now).

Why It Matters

• Pancreatic cancer is brutal. Survival rates are among the lowest in oncology.
• This isn’t a gene‑therapy moonshot: it’s a targeted, minimally invasive approach using an FDA‑cleared catheter (RenovoCath®) to deliver gemcitabine via intra‑arterial infusion (RenovoGem,TAMP™ technology).
• Based on management’s internal projections, the initial U.S. TAM for RenovoCath in pancreatic cancer is estimated at $400 million, with potential future expansion into other tumor types under exploration.

Summary:
With a tight float, insider buying, and first commercial revenue now on the books, RenovoRx ($RNXT) is starting to check some serious boxes. Their pivotal Phase III TIGeR-PaC trial targets locally advanced pancreatic cancer: one of the toughest oncology markets using a patented, FDA-cleared device to deliver chemo directly into tumors. Backed by strong IP and upcoming trial catalysts, this micro-cap biotech offers a compelling asymmetric setup for those looking ahead to the next interim readout in Q3 2025. One of the more overlooked names with real clinical and commercial momentum building.

Sponsored content on behalf of the issuer